Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4773MR)

This product GTTS-WQ4773MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4773MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3491MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ4734MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ11764MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ4835MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ11349MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ13099MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ1058MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ13409MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW